2016
Quasi-Experimental Evaluation of the Effectiveness of a Large-Scale Readmission Reduction Program
Jenq GY, Doyle MM, Belton BM, Herrin J, Horwitz LI. Quasi-Experimental Evaluation of the Effectiveness of a Large-Scale Readmission Reduction Program. JAMA Internal Medicine 2016, 176: 681. PMID: 27065180, DOI: 10.1001/jamainternmed.2016.0833.Peer-Reviewed Original ResearchConceptsDischarge patientsReadmissions Reduction ProgramControl populationReadmission ratesIntervention periodSame-hospital readmission ratesUrban academic medical centerTarget populationAdjusted readmission ratesOdds of readmissionHigh-risk patientsZip codesAdjusted admission ratesInterrupted time series analysisAcademic medical centerQuasi-experimental evaluationLogistic regression modelsReduction programsDischarge dispositionReadmission reduction effortsComparative interrupted time series analysisMedication reconciliationService patientsMean ageTransitional care
2015
Changing trends in type 2 diabetes mellitus treatment intensification, 2002-2010.
McCoy RG, Zhang Y, Herrin J, Denton BT, Mason JE, Montori VM, Smith SA, Shah ND. Changing trends in type 2 diabetes mellitus treatment intensification, 2002-2010. The American Journal Of Managed Care 2015, 21: e288-96. PMID: 26167776.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdolescentAdultAge FactorsAgedBlood GlucoseComorbidityDiabetes Mellitus, Type 2Drug Therapy, CombinationFemaleGlycated HemoglobinHumansHypoglycemic AgentsIncretinsInsurance Claim ReviewMaleMetforminMiddle AgedResidence CharacteristicsRetrospective StudiesSex FactorsSocioeconomic FactorsSulfonylurea CompoundsUnited StatesYoung AdultConceptsTreatment intensificationCox proportional hazards regression analysisNational administrative data setProportional hazards regression analysisRetrospective secondary data analysisDiabetes treatment intensificationOptimal diabetes careHazards regression analysisDiabetes-related complicationsAdults 18 yearsTreatment-naïve adultsNon-Hispanic whitesComorbidity burdenMetformin monotherapySulfonylurea useMetformin prescriptionThiazolidinedione useGlycemic controlKaplan-MeierMean ageDiabetes careSignificant confoundersSecondary data analysisAdministrative data setsDiabetes therapy
2013
Use of New Treatment Modalities for Non-small Cell Lung Cancer Care in the Medicare Population
Vest MT, Herrin J, Soulos PR, Decker RH, Tanoue L, Michaud G, Kim AW, Detterbeck F, Morgensztern D, Gross CP. Use of New Treatment Modalities for Non-small Cell Lung Cancer Care in the Medicare Population. CHEST Journal 2013, 143: 429-435. PMID: 23187634, PMCID: PMC3566996, DOI: 10.1378/chest.12-1149.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerStage I non-small cell lung cancerVideo-assisted thoracoscopic surgeryProportion of patientsOlder patientsCancer careNon-small cell lung cancer careEarly-stage non-small cell lung cancerStage non-small cell lung cancerEnd Results-Medicare databaseLung cancer careCell lung cancerCurative local therapyNew treatment modalitiesOverall useNew surgical techniqueType of treatmentNew radiation modalitiesRadiation therapy modalitiesSurgical resectionCurative therapyLocal therapyMore patientsThoracoscopic surgeryMean age